Should You Buy This Under-the-Radar Growth Stock?
Due to the current economic factors in play, mutual fund manager Vanguard expects the U.S. economy to grow by just 1.5% in 2022. For context, this is down significantly from its previous forecast of 3.5% GDP growth for this year.
The less optimistic growth outlook has heavily weighed on growth-oriented stocks. The tech-heavy Nasdaq Composite has dropped 27% so far this year. And the small-cap medical device stock AngioDynamics (NASDAQ: ANGO) hasn't fared too much better -- down 24% in 2022.
But does that make the cancer diagnosis/treatment and peripheral vascular disease device stock a buy for growth investors? Let's take a look at its fundamentals and valuation to decide.
Source Fool.com
